Co-Diagnostics (CODX) investor relations material

Company overview and business model

• Develops, manufactures, and sells reagents for molecular diagnostic tests targeting DNA/RNA, with a focus on infectious diseases and genetic traits.

• Proprietary Co-Primers® technology reduces false positives in PCR amplification, enabling more accurate and cost-effective diagnostics.

• Product portfolio includes PCR tests for COVID-19, influenza, tuberculosis, hepatitis B/C, HPV, malaria, chikungunya, dengue, and Zika, with regulatory approvals in multiple regions.

• Developing a portable PCR platform for point-of-care and at-home use, with ongoing clinical studies for a multiplex respiratory test (ABCR).

• Holds over 20 granted or pending patents, leveraging proprietary algorithms and molecular structures to maintain competitive margins.

Financial performance and metrics

• As of May 27, 2026, 3,685,314 shares of common stock were outstanding; up to 8,572,740 shares could be outstanding if all warrants are exercised.

• Proceeds from warrant exercises could total approximately $5.18 million, assuming all are exercised for cash.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders.

• Any proceeds from warrant exercises will be used for working capital and general corporate purposes.